Q1 2025 Alnylam Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Alnylam Pharmaceuticals Inc (ALNY) reported a 28% year-over-year growth in combined net product revenues, reaching $469 million.
- The US TTR franchise experienced a robust 45% year-over-year growth, driven by continued uptake in the hereditary polyneuropathy population.
- AMVUTTRA received expanded indication approvals for ATTR cardiomyopathy in the US and Brazil, with a positive CHMP opinion in the EU.
- The company reiterated its guidance for the year, expressing confidence in achieving sustainable non-GAAP profitability in 2025.
- Alnylam Pharmaceuticals Inc (ALNY) launched its 6th RNAi therapeutic, Qfitlia, for hemophilia A or B, in collaboration with Sanofi.
- Collaboration revenue decreased by 16% compared to the first quarter of last year, primarily due to a significant milestone achieved in the previous year.
- Gross margin on product sales is expected to decrease for the remainder of the year due to escalating AMVUTTRA royalty rates.
- Non-GAAP SG&A expenses increased by 12% in the first quarter compared to the same period last year, driven by investments in support of AMVUTTRA's cardiomyopathy launch.
- There is uncertainty related to potential evolution in policies, including tariffs and FDA personnel reorganization, which could impact the biotech industry.
- The company faces competition in the market, with new entrants potentially affecting its market share and growth trajectory.
Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Q1 2025 earnings conference call. (Operator Instructions) This call is being recorded on Thursday, May 1, 2025.
I would now extend the conference over to Alnylam. Please go ahead.
Good morning. I'm Christine Lindenboom, Chief Corporate Communications Officer at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer; Tolga Tanguler, Chief Commercial Officer; Pushkal Garg, Chief Medical Officer; and Jeff Poulton, Chief Financial Officer.
For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the Investors page of our website, investors.alynylam.com/events.
During today's call, as outlined in slide 2, Yvonne will offer introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress. Pushkal will review pipeline updates and clinical
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
